Death of the Pharma Salesman
Big Pharma is beginning to explore ways of moving beyond traditional corporate web sites to establish web presences designed to create relationships with their physician and consumer customers. As part of these efforts, some drug companies are experimenting with the e-detailing technologies offered by a growing number of start-ups.Although e-detailing will probably never replace pharmaceutical company sales reps, it may provide large drug companies with a cost-effective way of holding on to profitable niche products that would otherwise fall by the wayside as they focus attention on blockbusters. Perhaps even more significantly, emerging pharmaceutical firms and biotechs may be able to use the Internet to expand their sales and marketing infrastructure capabilities, without incurring huge infrastructure costs, and thus help those smaller companies compete more effectively against larger players.
You may also be interested in...
Manufacturers Should Map Processes, Bolster Quality Culture To Tackle Data Integrity Problems in The Microbiology Lab
To reduce the opportunity for data integrity failures in the microbiology lab, manufacturers should map out the workflow so that activities and expectations for employees are clearly spelled out. Having formalized processes will ensure that employees don’t cut corners.
Companies can have their EU centralized marketing authorization application and submission for an Article 58 opinion (on medicines for use in non-EU countries) reviewed in parallel by the European Medicines Agency. The simultaneous assessment can be helpful when drugs and vaccines are needed for both EU and non-EU populations.
The coronavirus could have serious adverse effects on regulatory procedures at both European Medicines Agency and EU member state level. A new business continuity plan describes how procedures will be prioritized if problems arise.